来他替尼 | 111358-88-4

• 物质功能分类: 原料药 - 抗肿瘤药 - 替尼类抗肿瘤药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 来他替尼
• 英文名称: lestaurtinib
• 英文别名: (9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3’,2’,1’-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one；(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one；(5S,6S,8R)-6-hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13(6H)-one；(5S,6S,8R)-6-hydroxy-6-(hydroxymethyl)-5-methyl-5,6,7,8,14,15-hexahydro-13H-16-oxa-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13-one；7-hydroxy-7-(hydroxymethyl)-8-methyl-5,6,7,8,13,14-hexahydro-15H-16-oxa-4b,8a,14- triaza-5,8- methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-15-one；(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one
• CAS: 111358-88-4
• 化学式: C₂₆H₂₁N₃O₄
• 分子量: 439.47
• InChiKey: UIARLYUEJFELEN-LROUJFHJSA-N

物化性质

• 熔点：
  215-220°C
• 沸点：
  723.0±60.0 °C(Predicted)
• 密度：
  1.70±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：>10mg/mL
• 稳定性/保质期：
  Photosensitive

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  33
• 可旋转键数：
  1
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  88.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 储存条件：
  干燥保存在-20°Celsius条件下

制备方法与用途

来他替尼是一种半合成的、口服生物有效的受体酪氨酸激酶抑制剂，已在治疗急性髓系白血病、慢性髓系白血病和急性淋巴细胞性白血病等疾病中显示出治疗效果。

作为一种多靶点吲哚并咔唑衍生物，来他替尼在体外有效抑制FLT3自身磷酸化。它是目前临床试验中最广泛研究的药物之一。目前正在进行多项针对成人和儿童白血病患者的晚期试验。

Lestaurtinib（CEP-701; KT-5555）是一种ATP竞争性的多激酶抑制剂，对Trk受体酪氨酸激酶家族具有强大的活性。其IC50值分别为：

• JAK2：0.9 nM
• TrkA：25 nM
• FLT3：3 nM

以下是具体的数据表：

靶点	IC50 (nM)
JAK2	0.9
TrkA	25
FLT3	3

反应信息

• 作为反应物：
  描述：

  来他替尼 在 4-二甲氨基吡啶 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (15S,16S,18R)-15-methylspiro[28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16,2'-oxirane]-3-one
  参考文献：
  名称：

  Synthesis, Modeling, and In Vitro Activity of (3‘S)-epi-K-252a Analogues. Elucidating the Stereochemical Requirements of the 3‘-Sugar Alcohol on trkA Tyrosine Kinase Activity

  摘要：

  Utilizing our recently published semisynthetic approach to the (3'S)-K-252a diastereomer, we report the first synthesis of the (3'R)-10 diastereomer and a set of related epimers, with the goal of defining the stereochemical role of the 3'-sugar hydroxyl group on trkA tyrosine kinase activity and selectivity. (3'R)-10 displayed potent trkA inhibitory activity with an IC50 value of 4 nM. The corresponding deshydroxy epimer (3'S)-14 was 7-fold more potent than its 3'R counterpart (natural stereochemistry) with a trkA IC50 value of 3 nM and demonstrated > 280-fold selectivity over PKC (IC50 = 850 nM). In cells, (3'S)-14 displayed potent inhibition of trkA autophosphorylation with an IC50 < 10 nM. Molecular modeling studies revealed that the X-OH, due to the inverted geometry, forms significant H-bonding interactions with Glu27 and Arg195, an interaction that is not attainable with the natural isomers.

  DOI：

  10.1021/jm040178m
• 作为产物：
  描述：

  (+)-抗生素K252A 在 锂硼氢 作用下， 以 四氢呋喃 为溶剂， 以81%的产率得到来他替尼
  参考文献：
  名称：

  Synthesis and kinase inhibitory activity of 3′-(S)-epi-K-252a

  摘要：

  The 3'-epi diastereomer of K-252a was synthesized with the goal of evaluating the stereochemical requirements of the 3'-sugar alcohol on kinase inhibitory activity. Inverting the 3'-alcohol resulted in a 20 nM inhibitor of VEGFR2 and a 1 nM inhibitor of TrkA tyrosine kinase. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00638-8

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017011776A1

  公开（公告）日：2017-01-19

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• [EN] CRYSTALLINE FORMS<br/>[FR] FORMES CRISTALLINES
  申请人：METCALF ANDREW T

  公开号：WO2019075108A1

  公开（公告）日：2019-04-18

  Provided herein are compound of Formula I-IV and pharmaceutically acceptable salts thereof which exhibit rearranged during transfection (RET) kinase inhibition. In particular, provided herein are novel crystalline forms of 4-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula I), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula II), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-(6-methoxynicotinoyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula III), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-hydroxy-4-(pyridin-2-ylmethyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula IV), and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds, processes for making the compounds, and the use of the compounds in therapy. More particularly, the application relates to novel crystalline forms of Formula I-IV and pharmaceutically acceptable salts thereof useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了化合物I-IV及其药学上可接受的盐，这些化合物在转染期间表现出重排（RET）激酶抑制作用。具体来说，本文提供了4-(6-(4-((6-甲氧基吡啶-3-基)甲基)哌嗪-1-基)吡啶-3-基)-6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡啶-3-碳腈（化合物I）、6-(2-羟基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮杂双环[3.1.1]庚烷-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-碳腈（化合物II）、6-(2-羟基-2-甲基丙氧基)-4-(6-(6-(6-甲氧基烟酰基)-3,6-二氮杂双环[3.1.1]庚烷-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-碳腈（化合物III）、6-(2-羟基-2-甲基丙氧基)-4-(6-(4-羟基-4-(吡啶-2-基甲基)哌啶-1-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-碳腈（化合物IV）及其药学上可接受的盐，包括含有这些化合物的药物组合物、制备这些化合物的方法，以及这些化合物在治疗中的应用。更具体地，本申请涉及化合物I-IV的新晶型及其药学上可接受的盐，用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括与RET相关的疾病和疾病。
• [EN] SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLO[2,3-D]PYRIMIDINES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2019143977A1

  公开（公告）日：2019-07-25

  Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：[插入Formula I]及其互变异构体、立体异构体和药学上可接受的盐和溶剂化合物，其中R1、R2和Ry具有规范中给定的含义，它们是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括与RET相关的疾病和紊乱。
• [EN] SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[3,4-D]PYRIMIDINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2019143991A1

  公开（公告）日：2019-07-25

  Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1 and R2 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供的是Formula I的化合物，以及其互变异构体和药学上可接受的盐和溶剂化合物，其中R1和R2具有规范中给定的含义，它们是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括与RET相关的疾病和疾病。
• Hydrolytically releasable prodrugs for sustained release nanoparticle formulations
  申请人：Alferiev Ivan

  公开号：US09233163B2

  公开（公告）日：2016-01-12

  A prodrug according to formula (I) wherein R2 is a residue of a drug, said drug having a hydroxyl group by which the COOR2 group is formed; Z is O or NH; m is 0 or 1; and R3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.

  根据公式（I）的专利药物前体，其中R2是药物的残基，所述药物具有通过COOR2基团形成的羟基；Z为O或NH；m为0或1；R3是包含疏水基团或聚合物残基的有机基团，前提是如果聚合物是羧甲基葡聚糖，则Z为0。该系统包括多个磁性纳米颗粒，其中包括上述描述的药物前体，支架和能够产生支架和/或磁性纳米颗粒临时磁化的均匀磁场源。用药物治疗医疗状况的方法包括向需要该药物的患者注射上述描述的药物前体，该药物前体在给药步骤后能够在患者体内释放药物。